Patients HCP
This site is for US residents only.
SEE STUDY RESULTS
Study results video

POWERFUL RESULTS WITH KESIMPTA

Over 1800 people with relapsing MS participated in 2 head-to-head studies comparing KESIMPTA to teriflunomide.* In the 1 to 2 years leading up to the studies, all of them had experienced a relapse or saw activity on an MRI scan.

*Study participants were aged 18 to 55. Each person received KESIMPTA 20 mg or teriflunomide 14 mg for up to 30 months. 465 people received KESIMPTA in Study 1, and 481 people in Study 2. 462 people received teriflunomide in Study 1, and 474 people in Study 2.

CUT RELAPSES BY MORE THAN HALF, AND REDUCED ACTIVE LESIONS BY OVER 90%† 

†In 2 studies versus teriflunomide.

PROVEN SUPERIOR†

In two clinical studies vs teriflunomide, KESIMPTA showed greater power to reduce relapses. In Study 1, people taking KESIMPTA experienced 51% fewer relapses. In Study 2, people taking KESIMPTA experienced 58% fewer relapses. *In 2 studies vs teriflunomide.
In two clinical studies, people taking KESIMPTA had fewer active Gd+ T1 lesions than those taking Aubagio (teriflunomide). In Study 1, people taking KESIMPTA experienced 98% fewer lesions (0.01 for KESIMPTA vs 0.46 for AUBAGIO on average per MRI scan). In Study 2, those taking KESIMPTA experienced 94% fewer lesions (0.03 for KESIMPTA vs 0.52 for AUBAGIO on average per MRI scan).
In two clinical studies, people taking KESIMPTA had fewer new or enlarging T2 lesions than those taking Aubagio (teriflunomide). In Study 1, people taking KESIMPTA experienced 82% fewer lesions (0.72 for KESIMPTA vs 4.00 for AUBAGIO per year). In Study 2, those taking KESIMPTA experienced 85% fewer lesions (0.64 for KESIMPTA vs 4.16 for AUBAGIO per year).
In two clinical studies vs teriflunomide, KESIMPTA showed greater power to slow disability progression. In Study 1 & 2 combined, people taking KESIMPTA were: at 3 months,† 34% less likely to experience disability progression; at 6 months,† 32% less likely to experience disability progression. *In 2 studies vs teriflunomide. †Based on whether disability progression was still present 3 and 6 months after disability symptoms started.
Gd+, gadolinium-enhancing; MRI, magnetic resonance imaging.
Maggie Image

MAGGIE S.
Mom, Recent Grad, and Real Patient
Started KESIMPTA: 2021

“Since starting KESIMPTA, I’ve had fewer relapses, which is really cool. I love seeing that it’s really working for me.”

Individual results may vary.

Up Next:

Understand the science behind KESIMPTA.

How It Works
 

Image of KESIMPTA pen
Sign Up Icon

Want more info to help you decide?

Find out why so many people are choosing KESIMPTA.

Sign Up Now
Phone Headset Icon

Want co-pay help?

96% of all prescriptions filled paid as little as $0 out of pocket cost when used with the Co-Pay Plus offer.§||

Learn About Support

Unless otherwise indicated, everyone featured on this webpage lives with relapsing MS, has taken KESIMPTA, and has been compensated for their time.
MS, multiple sclerosis; RMS, relapsing multiple sclerosis.
§Limitations apply. Valid only for those with private insurance. The Program includes the Co-Pay Plus offer, Plus Card (if applicable), and Rebate, with a combined annual limit up to $18,000. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient’s insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient’s insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice. See complete Terms & Conditions at start.kesimpta.com.
||2025 data on file.